You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy

    SBC: GLYTR THERAPEUTICS, INC.            Topic: 102

    AbstractTreatment of non-resectable recurrent/metastatic solid cancers is currently palliative only and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Antigen- targeting cancer immunotherapies such as bi-specific antibodies (eg Bi-specific T cell engager or BiTE’s) provide a unique approach for cancer immunotherapy. However, app ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. An Interactive Education Program to Reduce High Risk Behavior in Adolescents

    SBC: KLEIN BUENDEL, INC.            Topic: NICHD

    Internet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Chondrofluid for arthroscopic knee cartilage repair

    SBC: CARTILAGE INC            Topic: NIAMS

    PROJECT SUMMARY Minor injuries to articular cartilage can initiate a catabolic cascade, causing small defects to progress into larger, more symptomatic defects. Pain, lesion progression, and accelerated joint deterioration may be avoided with strategies that repair small defects with hyaline-like cartilage. The repair of chondral defects using arthroscopic techniques, performed in a minimally inva ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Advanced optics to unlock large field-of-view multiphoton imaging for neuroscience and beyond

    SBC: PACIFICOPTICA LLC            Topic: 101

    Project summary Currently available optical components limit biomedical imaging. In particular, in neurobiology, standard microscope components limit the field-of-view and speed of imaging of neuronal activity. Through prior work on BRAIN Initiative project, we have developed approaches for new optical components that expand the field-of-view 5 to 50 times over standard microscopes, with no loss i ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 300

    PROJECT SUMMARY Crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. CD affects up to one million Americans and is a type of inflammatory bowel disease. CD is driven by CD4 T cells with a significant role for TH1 and TH17 cells and additional involvement of B cells. Current therapies for CD ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Demonstrating miniaturized production of a KOR PET tracer as a proof-of-concept for low-cost distribution of nascent PET neurotracers

    SBC: DropletPharm Inc.            Topic: NIDA

    PROJECT SUMMARY / ABSTRACT Positron-emission tomography (PET) studies play a critical role in many areas of neurological health by enabling quantitative in vivo measurements of specific neuroreceptor systems (e.g. receptor density, drug occupancy, endogenous ligand occupancy) to (i) evaluate fundamental hypotheses about disease or (ii) aid in the development of novel treatments targeting those rec ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

    SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC            Topic: NIA

    Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of recombinant bovine lactoferrin and N-linked glycan effects on infant gut health and immunity

    SBC: TURTLETREE LABS INC.            Topic: NICHD

    Project Summary/Abstract Most infants currently rely on infant formula (IF) to meet their nutritional needs. However, existing infant formula is functionally inferior because it lacks breast milk bioactive proteins that are crucial to infant health and development. Consequently, formula-fed infants have increased risk of morbidity and mortality. Current technology limits the ability to add bioacti ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel non-contact, label-free multimodality imager that provides real-time intraoperative identification of nerves within the surgical field-of-view to facilitate the prevention of unintended nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical complications, e.g., chronic pain. In the United St ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government